Cristal Therapeutics

Cristal Therapeutics (formerly Cristal Delivery) is developing the nanomedicines based on its proprietary CriPec platform for cancer and inflammation. The technology platform consists of tunable polymers, biodegradable drug linkers, and targeting ligands that enable the design and development of targeted nanomedicines. Its lead product is CriPec docetaxel for the treatment of solid tumors is in phase 2 trials. The company was founded in 2011 and headquartered in Maastricht, Netherlands. It has raised $21.2M in series b funding, with backing from Europa, Thuja Capital, BioGeneration Ventures, Brightlands Venture Partners, and others. The company operates in the Life Sciences - Drug Delivery, High Tech - Nanotechnology, Life Sciences - Oncology space. Provides nanomedicines based ON CriPec platform for cancer and inflammation disorder.